New Research Presented at 4th Collaborative Meeting of CMSC and ACTRIMS Expands Understanding of MS-Related Walking …

HAWTHORNE, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present research at the 4th Collaborative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) that examines the impact of walking impairment on different aspects of the lives of people with multiple sclerosis (MS), as well as the use of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg in the United States. The six company-sponsored posters will be presented on Friday, June 1 at the CMSC/ACTRIMS meeting, being held in San Diego, CA.

AMPYRA is the only FDA-approved therapy to improve walking in people with MS. Although walking is one of our most critical functional capabilities, and is impaired in more than half of all MS patients, there has been limited research on the pharmacologic treatment of walking impairment in MS. In part this was due to the lack of treatment options prior to AMPYRAs availability in 2010, said Ron Cohen, M.D., Acorda Therapeutics President and CEO. By supporting research that explores ways to better characterize walking impairment and more precisely quantify its impact in real-world settings, we can gain a better understanding of how improved walking may benefit people with MS.

Acorda-sponsored research being presented at the CMSC/ACTRIMS meetings includes:

More detailed information on scientific sessions and data presentations at the CMSC/ACTRIMS meeting can be found on the conference website (http://www.cmsc-actrims.org/).

AMPYRA is known as prolonged-, modified, or sustained-release fampridine (FAMPYRA) in some countries outside the United States.

Important Safety Information

AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.

AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrCl less-than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Read the rest here:
New Research Presented at 4th Collaborative Meeting of CMSC and ACTRIMS Expands Understanding of MS-Related Walking ...